Comparison of prilocaine and mepivacaine for perianal surgery in an outpatient setting

Submission date 15/05/2012	Recruitment status No longer recruiting	Prospectively registered
		[_] Protocol
Registration date	Overall study status	[] Statistical analysis plan
25/07/2012	Completed	[_] Results
Last Edited	Condition category	Individual participant data
25/07/2012	Digestive System	[] Record updated in last year

Plain English summary of protocol

Background and study aims

Minor colorectal diseases such as condyloma (infection of the genitals), fissures or haemorrhoids are very common amongst the adult population. If surgical treatment is necessary, procedures are usually performed in an ambulatory setting (outpatient surgery/day care). Spinal anaesthesia with small amounts of hyperbaric local anaesthetics seems to be more efficient than other anaesthesia techniques. In July 2010, prilocaine 2%, a new hyperbaric local anaesthetic, was introduced to the market. Compared to formerly used mepivacaine, prilocaine seems to have a shorter time of drug-action and a lower rate of adverse side effects. Therefore prilocaine 2% may be the preferred anaesthetic for perianal outpatient surgery. The aim of this study is to compare prilocaine and mepivacaine regarding adverse side effects, amount of additional analgesics needed as well as the duration of patients stay in day care.

Who can participate?

Every patient suffering from minor colorectal diseases aged 18 to 80 can take part in this study, except for patients who have the following: contraindications against spinal anaesthesia, not eligible for day surgery, allergies against local anaesthetics or drugs used for postoperative analgesia.

What does the study involve?

Participants are randomly allocated to either 0.5ml of hyperbaric prilocaine 2% or 0.5ml of hyperbaric mepivacaine 4%. The expansion of sensory and motor blocks are tested. After the procedure, the period of time until the patient is able to void (pass urine), to get up and walk without assistance as well as the time span until the patient is eligible for discharge are evaluated. The occurence of pain as well as the amount of postoperative analgesics needed are documented. One week after the operation, there is a telephone interview with the patient. This includes questions about the occurence of transient neurologic symptoms (a symmetrical bilateral pain in the back or buttocks or pain radiating to the lower extremities after recovery from spinal anesthesia) or postpunctural headache. The interviewer also assesses the patient`s overall satisfaction concerning anaesthesia.

What are the possible benefits and risks of participating? There will be no immediate direct benefit to those taking part. But there should be benefits to future patients undergoing minor perianal surgery in an ambulatory setting by establishing a drug with fewer adverse side effects for this purpose. Both drugs compared in this study are well established. There are no furthers risks than those of regular spinal anaesthesia in an ambulatory setting.

Where is the study run from?

The study has been set up by the Department of Anaesthesiology and Surgical Intensive Care Medicine, University Medical Centre Mannheim.

When is the study starting?

The study started at the day surgery centre, University Medical Centre Mannheim on July 26 2011. Participants will be enrolled on the study for a period of one week starting with the day of surgery.

Who is funding the study? Funding has been provided by the University Medical Centre Mannheim.

Who is the main contact? Marc D. Schmittner, MD, PhD marc.schmittner@umm.de

Contact information

Type(s) Scientific

Contact name Dr Marc D Schmittner

Contact details

University Medical Centre Mannheim [Universitätsmedizin Mannheim] Department of Anaesthesiology and Intensive Care Medicine Theodor-Kutzer-Ufer 1-3 Mannheim Germany 68167

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers N/A

Study information

Scientific Title

Comparison of 0.5ml hyperbaric prilocaine 2% versus 0.5ml hyperbaric mepivacaine 4% for lowdose spinal anaesthesia in patients undergoing perianal surgery in an ambulatory setting

Study objectives

In 2010 hyperbaric prilocaine 2% was introduced in the German market. Evidence based data comparing hyperbaric prilocaine 2% versus hyperbaric mepivacaine 4% for perianal surgery does not exist. In this trial we compare the expansion of low dose spinal anaesthesia, the incidence of transient neurological symptoms (TNS) and the duration of stay in hospital comparing 0.5ml hyperbaric prilocaine 2% vs. 0,5ml hyperbaric mepivacaine 4%.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Medical Ethics Committee II, Faculty of Medicine, Ruprecht Karl University of Heidelberg [Medizinische Ethikkommission II: MEdizinische Fakultät Mannheim der Ruprecht-Karls-Universität Heidelberg], 20 July 2011, ref. AZ.:2011-298N-MA

Study design Randomised controlled double-blinded single-center trial

Primary study design Interventional

Secondary study design Randomised controlled trial

Study setting(s) Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Colorectal diseases

Interventions

Participants are randomised (1:1) and assigned to a dose of either 0.5ml of hyperbaric prilocaine 2% or of 0.5ml of hyperbaric mepivacaine 4%.

The expansion of sensory and motor blocks are tested. After the procedure, the period of time until the patient is able to void, to get up and walk without assistance as well as the time span until the patient is eligible for discharge are evaluated. The occurence of pain as well as the amount of postoperative analgesics needed are documented. One week postoperative a telephone-interview with the patient is carried out. This includes questions about the occurence of transient neurologic symtoms or postpunctural headache. The interviewer also assess the patient's overall satisfaction concerning anaesthesia.

Intervention Type

Other

Phase Not Applicable

Primary outcome measure

- 1. Period of time till discharge
- 2. Occurence of transient neurologic symptoms

Secondary outcome measures

- 1. Occurence of pain
- 2. Patients satisfaction
- 3. Expansion of sensory and motor block
- 4. Time span until patient is able walk and void

Overall study start date

26/07/2011

Completion date

26/05/2012

Eligibility

Key inclusion criteria

1. Patients (male or female) undergoing minor perianal surgery

2. Aged 18 - 80 years

3. American Society of Anesthesiologists (ASA) physical status I-III

Participant type(s) Patient

Age group Adult

Lower age limit 18 Years

Sex Both

Target number of participants 160

Key exclusion criteria

1. Contraindications for spinal anaesthesia

2. Allergy to diclofenac, metamizole, paracetamole, piritramid or one of the local anaesthetics used

3. Patients with language barriers

Date of first enrolment 26/07/2011

Date of final enrolment 26/05/2012

Locations

Countries of recruitment Germany

Study participating centre University Medical Centre Mannheim [Universitätsmedizin Mannheim] Mannheim Germany 68167

Sponsor information

Organisation University Medical Centre Mannheim [Universitätsmedizin Mannheim] (Germany)

Sponsor details Department of Anaesthesiology and Intensive Care Medicine Theodor-Kutzer-Ufer 1-3 Mannheim Germany 68167

Sponsor type University/education

Website http://www.umm.de/

ROR https://ror.org/05sxbyd35

Funder(s)

Funder type University/education

Funder Name University Medical Centre Mannheim [Universitätsmedizin Mannheim] (Germany)

Results and Publications

Publication and dissemination plan Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary Not provided at time of registration